O	0	7	Insulin	Insulin	NN	B-NP
O	7	8	-	-	HYPH	I-NP
O	8	12	like	like	JJ	I-NP
O	13	19	growth	growth	NN	I-NP
O	20	26	factor	factor	NN	I-NP
O	26	27	-	-	HYPH	B-NP
O	27	28	I	I	NN	I-NP
O	29	37	receptor	receptor	NN	I-NP
O	37	38	-	-	HYPH	B-VP
O	38	46	mediated	mediate	VBN	B-NP
O	47	61	vasculogenesis	vasculogenesis	NN	I-NP
O	61	62	/	/	SYM	B-VP
O	62	74	angiogenesis	angiogenesis	NN	B-NP
O	75	77	in	in	IN	B-PP
O	78	83	human	human	JJ	B-NP
B-Organ	84	88	lung	lung	NN	I-NP
O	89	100	development	development	NN	I-NP
O	100	101	.	.	.	O

O	102	105	The	The	DT	B-NP
O	106	116	structural	structural	JJ	I-NP
O	117	120	and	and	CC	I-NP
O	121	131	functional	functional	JJ	I-NP
O	132	143	development	development	NN	I-NP
O	144	146	of	of	IN	B-PP
O	147	150	the	the	DT	B-NP
B-Anatomical_system	151	160	pulmonary	pulmonary	JJ	I-NP
I-Anatomical_system	161	167	system	system	NN	I-NP
O	168	170	is	be	VBZ	B-VP
O	171	180	dependent	dependent	JJ	B-ADJP
O	181	185	upon	upon	IN	B-PP
O	186	197	appropriate	appropriate	JJ	B-NP
O	198	203	early	early	JJ	I-NP
O	204	219	vascularization	vascularization	NN	I-NP
O	220	222	of	of	IN	B-PP
O	223	226	the	the	DT	B-NP
B-Organ	227	236	embryonic	embryonic	JJ	I-NP
I-Organ	237	241	lung	lung	NN	I-NP
O	241	242	.	.	.	O

O	243	246	Our	Our	PRP$	B-NP
O	247	255	previous	previous	JJ	I-NP
O	256	258	in	in	FW	I-NP
O	259	264	vitro	vitro	FW	I-NP
O	265	272	studies	study	NNS	I-NP
O	273	275	in	in	IN	B-PP
O	276	277	a	a	DT	B-NP
O	278	281	rat	rat	NN	I-NP
O	282	287	model	model	NN	I-NP
O	288	297	indicated	indicate	VBD	B-VP
O	298	302	that	that	IN	B-SBAR
O	303	310	insulin	insulin	NN	B-NP
O	310	311	-	-	HYPH	B-NP
O	311	315	like	like	JJ	I-NP
O	316	322	growth	growth	NN	I-NP
O	323	329	factor	factor	NN	I-NP
O	329	330	-	-	HYPH	B-NP
O	330	331	I	I	NN	I-NP
O	332	333	(	(	(	O
O	333	336	IGF	IGF	NN	B-NP
O	336	337	-	-	HYPH	I-NP
O	337	338	I	I	NN	I-NP
O	338	339	)	)	)	O
O	340	342	is	be	VBZ	B-VP
O	343	344	a	a	DT	B-NP
O	345	351	potent	potent	JJ	I-NP
O	352	362	angiogenic	angiogenic	JJ	I-NP
O	363	368	agent	agent	NN	I-NP
O	369	372	for	for	IN	B-PP
B-Cell	373	378	fetal	fetal	JJ	B-NP
I-Cell	379	383	lung	lung	NN	I-NP
I-Cell	384	395	endothelial	endothelial	JJ	I-NP
I-Cell	396	401	cells	cell	NNS	I-NP
O	401	402	.	.	.	O

O	403	405	To	To	TO	B-VP
O	406	412	assess	assess	VB	I-VP
O	413	416	its	its	PRP$	B-NP
O	417	421	role	role	NN	I-NP
O	422	424	on	on	IN	B-PP
O	425	430	human	human	JJ	B-NP
B-Multi-tissue_structure	431	439	vascular	vascular	JJ	I-NP
B-Organ	440	444	lung	lung	NN	I-NP
O	445	456	development	development	NN	I-NP
O	456	457	,	,	,	O
O	458	460	we	we	PRP	B-NP
O	461	466	first	first	RB	B-ADVP
O	467	475	examined	examine	VBD	B-VP
O	476	479	the	the	DT	B-NP
O	480	490	expression	expression	NN	I-NP
O	491	493	of	of	IN	B-PP
O	494	497	IGF	IGF	NN	B-NP
O	497	498	-	-	HYPH	B-NP
O	498	499	I	I	NN	I-NP
O	499	500	/	/	SYM	I-NP
O	500	502	II	II	NN	I-NP
O	503	506	and	and	CC	I-NP
O	507	510	IGF	IGF	NN	I-NP
O	511	519	receptor	receptor	NN	I-NP
O	520	524	type	type	NN	I-NP
O	525	526	I	I	CD	I-NP
O	527	528	(	(	(	O
O	528	531	IGF	IGF	NN	B-NP
O	531	532	-	-	HYPH	B-NP
O	532	534	IR	IR	NN	I-NP
O	534	535	)	)	)	O
O	536	538	in	in	IN	B-PP
O	539	544	human	human	JJ	B-NP
B-Tissue	545	554	embryonic	embryonic	JJ	I-NP
O	555	558	and	and	CC	I-NP
B-Tissue	559	564	fetal	fetal	JJ	I-NP
I-Tissue	565	569	lung	lung	NN	I-NP
I-Tissue	570	577	tissues	tissue	NNS	I-NP
O	578	580	at	at	IN	B-PP
O	581	582	4	4	CD	B-NP
O	582	583	-	-	HYPH	I-NP
O	583	585	12	12	CD	I-NP
O	586	588	wk	wk	NN	I-NP
O	589	591	of	of	IN	B-PP
O	592	601	gestation	gestation	NN	B-NP
O	601	602	.	.	.	O

O	603	622	Immunohistochemical	Immunohistochemical	JJ	B-NP
O	623	626	and	and	CC	I-NP
O	627	629	in	in	FW	I-NP
O	630	634	situ	situ	FW	I-NP
O	635	648	hybridization	hybridization	NN	I-NP
O	649	656	studies	study	NNS	I-NP
O	657	665	revealed	reveal	VBD	B-VP
O	666	669	the	the	DT	B-NP
O	670	678	presence	presence	NN	I-NP
O	679	681	of	of	IN	B-PP
O	682	685	IGF	IGF	NN	B-NP
O	685	686	-	-	HYPH	I-NP
O	686	687	I	I	NN	I-NP
O	687	688	/	/	SYM	I-NP
O	688	690	II	II	CD	I-NP
O	690	691	-	-	HYPH	I-NP
O	691	694	IGF	IGF	NN	I-NP
O	694	695	-	-	HYPH	I-NP
O	695	697	IR	IR	NN	I-NP
O	698	705	ligands	ligand	NNS	I-NP
O	706	709	and	and	CC	O
O	710	714	mRNA	mRNA	NN	B-NP
O	715	726	transcripts	transcript	NNS	I-NP
O	727	729	in	in	IN	B-PP
B-Organ	730	739	embryonic	embryonic	JJ	B-NP
I-Organ	740	745	lungs	lung	NNS	I-NP
O	746	748	as	as	RB	B-ADVP
O	749	754	early	early	RB	I-ADVP
O	755	757	as	as	IN	B-PP
O	758	759	4	4	CD	B-NP
O	760	762	wk	wk	NN	I-NP
O	763	772	gestation	gestation	NN	I-NP
O	772	773	.	.	.	O

O	774	789	Immunotargeting	Immunotargeting	NN	B-NP
O	790	795	using	use	VBG	B-VP
O	796	798	an	an	DT	B-NP
O	799	803	anti	anti	AFX	I-NP
O	803	804	-	-	HYPH	I-NP
O	804	807	IGF	IGF	NN	I-NP
O	807	808	-	-	HYPH	O
O	808	810	IR	IR	NN	B-NP
O	811	823	neutralizing	neutralize	VBG	B-VP
O	824	832	antibody	antibody	NN	B-NP
O	833	835	on	on	IN	B-PP
O	836	841	human	human	JJ	B-NP
B-Organ	842	847	fetal	fetal	JJ	I-NP
I-Organ	848	852	lung	lung	NN	I-NP
I-Organ	853	861	explants	explant	NNS	I-NP
O	862	874	demonstrated	demonstrate	VBD	B-VP
O	875	876	a	a	DT	B-NP
O	877	888	significant	significant	JJ	I-NP
O	889	897	blockade	blockade	NN	I-NP
O	898	900	of	of	IN	B-PP
O	901	904	IGF	IGF	NN	B-NP
O	904	905	-	-	HYPH	B-NP
O	905	907	IR	IR	NN	I-NP
O	908	917	signaling	signaling	NN	I-NP
O	917	918	.	.	.	O

O	919	931	Inactivation	Inactivation	NN	B-NP
O	932	934	of	of	IN	B-PP
O	935	938	IGF	IGF	NN	B-NP
O	938	939	-	-	HYPH	B-NP
O	939	941	IR	IR	NN	I-NP
O	942	950	resulted	result	VBD	B-VP
O	951	953	in	in	IN	B-PP
O	954	955	a	a	DT	B-NP
O	956	960	loss	loss	NN	I-NP
O	961	963	of	of	IN	B-PP
B-Cell	964	975	endothelial	endothelial	JJ	B-NP
I-Cell	976	981	cells	cell	NNS	I-NP
O	981	982	,	,	,	O
O	983	994	accompanied	accompany	VBN	B-VP
O	995	997	by	by	IN	B-PP
O	998	1006	dramatic	dramatic	JJ	B-NP
O	1007	1014	changes	change	NNS	I-NP
O	1015	1017	in	in	IN	B-PP
B-Organ	1018	1023	fetal	fetal	JJ	B-NP
I-Organ	1024	1028	lung	lung	NN	I-NP
O	1029	1036	explant	explant	NN	I-NP
O	1037	1047	morphology	morphology	NN	I-NP
O	1047	1048	.	.	.	O

O	1049	1057	Terminal	Terminal	JJ	B-NP
O	1058	1069	transferase	transferase	NN	I-NP
O	1070	1074	dUTP	dUTP	NN	I-NP
O	1075	1078	end	end	NN	I-NP
O	1078	1079	-	-	HYPH	O
O	1079	1087	labeling	label	VBG	B-VP
O	1088	1093	assay	assay	NN	B-NP
O	1094	1097	and	and	CC	I-NP
O	1098	1101	TEM	TEM	NN	I-NP
O	1102	1109	studies	study	NNS	I-NP
O	1110	1112	of	of	IN	B-PP
O	1113	1117	anti	anti	AFX	B-NP
O	1117	1118	-	-	HYPH	I-NP
O	1118	1121	IGF	IGF	NN	I-NP
O	1121	1122	-	-	HYPH	I-NP
O	1122	1124	IR	IR	NN	I-NP
O	1124	1125	-	-	HYPH	B-NP
O	1125	1132	treated	treat	VBN	I-NP
B-Organ	1133	1138	lungs	lung	NNS	I-NP
O	1139	1151	demonstrated	demonstrate	VBD	B-VP
O	1152	1160	numerous	numerous	JJ	B-NP
O	1161	1170	apoptotic	apoptotic	JJ	I-NP
B-Cell	1171	1182	mesenchymal	mesenchymal	JJ	I-NP
I-Cell	1183	1188	cells	cell	NNS	I-NP
O	1188	1189	.	.	.	O

O	1190	1193	Rat	Rat	NN	B-NP
B-Organ	1194	1203	embryonic	embryonic	JJ	I-NP
I-Organ	1204	1208	lung	lung	NN	I-NP
O	1209	1216	explant	explant	NN	I-NP
O	1217	1224	studies	study	NNS	I-NP
O	1225	1232	further	further	RBR	B-ADVP
O	1233	1242	validated	validate	VBD	B-VP
O	1243	1246	the	the	DT	B-NP
O	1247	1257	importance	importance	NN	I-NP
O	1258	1260	of	of	IN	B-PP
O	1261	1264	the	the	DT	B-NP
O	1265	1268	IGF	IGF	NN	I-NP
O	1268	1269	-	-	HYPH	B-NP
O	1269	1272	IGF	IGF	NN	I-NP
O	1272	1273	-	-	HYPH	I-NP
O	1273	1275	IR	IR	NN	I-NP
O	1276	1282	system	system	NN	I-NP
O	1283	1286	for	for	IN	B-PP
B-Multi-tissue_structure	1287	1291	lung	lung	NN	B-NP
I-Multi-tissue_structure	1292	1300	vascular	vascular	JJ	I-NP
O	1301	1312	development	development	NN	I-NP
O	1312	1313	.	.	.	O

O	1314	1319	These	These	DT	B-NP
O	1320	1324	data	datum	NNS	I-NP
O	1325	1332	provide	provide	VBP	B-VP
O	1333	1336	the	the	DT	B-NP
O	1337	1342	first	first	JJ	I-NP
O	1343	1356	demonstration	demonstration	NN	I-NP
O	1357	1359	of	of	IN	B-PP
O	1360	1363	IGF	IGF	NN	B-NP
O	1363	1364	-	-	HYPH	I-NP
O	1364	1365	I	I	NN	I-NP
O	1365	1366	/	/	SYM	I-NP
O	1366	1368	II	II	CD	I-NP
O	1369	1379	expression	expression	NN	I-NP
O	1380	1382	in	in	IN	B-PP
O	1383	1386	the	the	DT	B-NP
O	1387	1392	human	human	JJ	I-NP
B-Organ	1393	1397	lung	lung	NN	I-NP
O	1398	1400	in	in	IN	B-PP
O	1401	1406	early	early	JJ	B-NP
O	1407	1416	gestation	gestation	NN	I-NP
O	1417	1420	and	and	CC	O
O	1421	1429	indicate	indicate	VBP	B-VP
O	1430	1434	that	that	IN	B-SBAR
O	1435	1438	the	the	DT	B-NP
O	1439	1442	IGF	IGF	NN	I-NP
O	1443	1449	family	family	NN	I-NP
O	1450	1452	of	of	IN	B-PP
O	1453	1459	growth	growth	NN	B-NP
O	1460	1467	factors	factor	NNS	I-NP
O	1467	1468	,	,	,	O
O	1469	1475	acting	act	VBG	B-VP
O	1476	1483	through	through	IN	B-PP
O	1484	1487	the	the	DT	B-NP
O	1488	1491	IGF	IGF	NN	I-NP
O	1491	1492	-	-	HYPH	B-NP
O	1492	1494	IR	IR	NN	I-NP
O	1494	1495	,	,	,	O
O	1496	1498	is	be	VBZ	B-VP
O	1499	1507	required	require	VBN	I-VP
O	1508	1510	as	as	IN	B-PP
O	1511	1512	a	a	DT	B-NP
O	1513	1521	survival	survival	NN	I-NP
O	1522	1528	factor	factor	NN	I-NP
O	1529	1535	during	during	IN	B-PP
O	1536	1542	normal	normal	JJ	B-NP
O	1543	1548	human	human	JJ	I-NP
B-Organ	1549	1553	lung	lung	NN	I-NP
O	1554	1569	vascularization	vascularization	NN	I-NP
O	1569	1570	.	.	.	O

